title: Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: a randomised, controlled trial.
abstract: BACKGROUND
  Common mental disorders are associated with substantial morbidity and disability in developing countries, but there are no data for efficacy of treatment. We aimed to assess the efficacy and cost-effectiveness of antidepressant and psychological treatment for common mental disorders in general health-care settings.
  
  
  METHODS
  We did a randomised, placebo-controlled trial (double-blind for the antidepressant group) in general outpatient clinics in two district hospitals in Goa, India. Consecutive eligible adults who scored more than 15 on the Revised Clinical Interview Schedule (n=450) were randomly assigned to antidepressant (fluoxetine), placebo, or psychological treatment. Antidepressant or placebo was provided for up to 6 months. Up to six sessions of psychological treatment were provided by trained therapists. The primary outcome was psychiatric morbidity; secondary outcomes were disability and costs. Outcome measurements were done at 2, 6, and 12 months. Intention-to-treat analyses were done with linear regression.
  
  
  RESULTS
  80% of patients were reviewed; the number of drop-outs was similar in all three groups. Psychiatric outcome was significantly better with antidepressant than with placebo at 2 months (p=0.02; standardised effect size 0.3), but not over the 2-12 month period (p=0.10); antidepressants were significantly more cost effective than placebo in the short term and long term (p<0.05). Psychological treatment was not more effective than placebo for any outcome during either period.
  
  
  CONCLUSIONS
  Affordable antidepressants such as fluoxetine should be the treatment of choice for common mental disorders in general health-care settings in India, since they are associated with improved clinical and economic outcomes, especially in the short term.
authors.affiliation: Section of Epidemiology, Institute of Psychiatry, London, UK. vikpat@goatelecom.com
authors.forename: Vikram
authors.initials: V
authors.lastname: Patel
authors.forename: Daniel
authors.initials: D
authors.lastname: Chisholm
authors.forename: Sophia
authors.initials: S
authors.lastname: Rabe-Hesketh
authors.forename: Fiona
authors.initials: F
authors.lastname: Dias-Saxena
authors.forename: Gracy
authors.initials: G
authors.lastname: Andrew
authors.forename: Anthony
authors.initials: A
authors.lastname: Mann
mesh_terms: D018687:Antidepressive Agents, Second-Generation / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007194:India; D016015:Logistic Models; D008297:Male; D001523:Mental Disorders / Q000145:classification / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D011613:Psychotherapy / Q000191:economics*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine